Recent News

• 08.03.2026 - BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
• 08.03.2026 - BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
• 07.22.2026 - BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
• 07.10.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 07.02.2026 - Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
• 07.01.2026 - BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
• 06.28.2026 - BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
• 06.23.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 06.22.2026 - BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
• 05.27.2026 - BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9

Recent Filings

• 08.03.2026 - 4 Statement of changes in beneficial ownership of securities
• 08.03.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.27.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.24.2026 - S-3ASR Automatic shelf registration statement of securities of well-known seasoned issuers
• 07.24.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 07.22.2026 - 8-K Current report
• 07.22.2026 - EX-99.1 EX-99.1
• 07.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.13.2026 - 4 Statement of changes in beneficial ownership of securities
• 07.10.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership